In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among ... reduction in body weight from baseline on the basis of receiving ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...

For millions of people struggling with weight loss in 2025, it feels like the ... A prescription drug called Tirzepatide is sold under the brand name Mounjaro. Mounjaro has made headlines for ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...